Clindamycin phosphate

磷酸克林霉素

Report date: 2026/02/10 20:00:22
QIDP

Base Information

Drug NameClindamycin phosphate
Drug Alias NameEvoclinCleocinDalacin-SXaciatoU-28508 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Action50S ribosomal subunit inhibitors
Targets50S ribosomal subunit
Therapy Area/IndicationsSusceptible anaerobic bacteria infectionLower Respiratory Tract InfectionsPrevotella infection +[21] 
Global Approved IndicationsPrevotella infectionAcne VulgarisPneumococcal Infections +[8] 
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1980/07/09
Country/TerritoryUnited StatesPuerto RicoDominican Republic +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesOrganonPfizer IncPfizer Japan Inc +[7] 
Inactive CompaniesDaré Bioscience IncActavis IncAbraxis Pharmaceutical Products Inc +[4] 
Active IndicationsLower Respiratory Tract InfectionsPrevotella infectionAcute bacterial skin and skin structure infections +[16] 
Inactive IndicationsSusceptible anaerobic bacteria infectionAcne VulgarisVulvitis +[5] 

Other Information

ATC CodeD10AF01G01AA10J01FF01
Related LinksWikipediaDrugBankKEGG